Breaking News Instant updates and real-time market news.

P

Pandora

$9.29

-0.135 (-1.43%)

, BLMN

Bloomin' Brands

$20.59

-0.3 (-1.44%)

10:23
05/19/17
05/19
10:23
05/19/17
10:23

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Macquarie analyst Amy Yong downgraded Pandora (P) to Neutral from Outperform and trimmed her price target to $11 saying potential M&A is to "tough to call" and fundamentals are "choppy." The analyst believes Pandora could sell Ticketfly which would free up financial capacity and help management focus on the core business, but said if neither a sale or M&A materializes, its standalone strategy will be the focus. 2. Wells Fargo analyst Jeff Farmer downgraded Bloomin' Brands (BLMN) to Market Perform saying Street estimates could prove aggressive due to labor costs while share repurchases are decelerating. 3. Deutsche Bank analyst Tiffany Kanaga downgraded The Buckle (BKE) to Sell, citing a lack of near-term support post the Q1 report and continued long-term concerns. 4. HSBC analyst Steve McGarry downgraded Shire (SHPG) to Reduce, saying that while the hereditary angioedema data are positive, investors should avoid the "hemophilia risk." 5. RBC Capital analyst Matthew Hedberg downgraded Symantec (SYMC) to Sector Perform from Outperform, citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

P

Pandora

$9.29

-0.135 (-1.43%)

BLMN

Bloomin' Brands

$20.59

-0.3 (-1.44%)

BKE

The Buckle

$16.23

-1.1715 (-6.73%)

SHPG

Shire

$190.00

7.83 (4.30%)

SYMC

Symantec

$29.74

-0.38 (-1.26%)

  • 06

    Jun

  • 08

    Jun

  • 26

    Jun

P Pandora
$9.29

-0.135 (-1.43%)

05/19/17
MACQ
05/19/17
DOWNGRADE
Target $11
MACQ
Neutral
Pandora downgraded to Neutral from Outperform at Macquarie
Macquarie analyst Amy Yong downgraded Pandora (P) to Neutral from Outperform and trimmed her price target to $11 saying potential M&A is to "tough to call" and fundamentals are "choppy." Yong said Liberty SiriusXM (LSXMA) is expected to remain financially disciplined and opportunistic, and unlikely to pay a substantial premium for Pandora. The analyst believes Pandora could sell Ticketfly which would free up financial capacity and help management focus on the core business, but said if neither a sale or M&A materializes, its standalone strategy will be the focus. As a result, Yong trimmed Pandora ad and subscription estimates to reflect the increasingly competitive environment and said profitability remains a question.
05/18/17
RHCO
05/18/17
NO CHANGE
RHCO
Pandora could be acquired for $12 per share, says SunTrust
After The New York Post reported that merger talks between Pandora (P) and Sirius XM (SIRI) have resumed, SunTrust analyst Matthew Thornton says that Pandora can be acquired for a per share price of "$9+-$12+." He thinks that other suitors besides Sirius could include Tencent (TCEHY), Spotify, and Google (GOOG,GOOGL) However, the analyst adds that Pandora's new features have not impacted the company's fundamentals significantly, while the launch of its new products has been delayed. He cut his price target on the shares to $10.50 from $16 but kept a Buy rating on the stock.
05/17/17
05/17/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Disney (DIS) downgraded to Neutral from Outperform at Macquarie with analyst Tim Nollen saying the company's exposure to cable and "outsized" subscriber declines at ESPN "have again become a focal point in investors' minds." 2. Pandora (P) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Heath Terry saying he was wrong in thinking the market would focus on new subscription products and a return to profitability by the fourth quarter. 3. Square (SQ) downgraded to Neutral from Buy at BTIG with analyst Mark Palmer citing valuation following the strong rally and removed his $20 price target. 4. AMD (AMD) downgraded to Hold from Buy at Loop Capital with analyst Betsy Van Hees saying she believes the stock is fairly valued and is already pricing in "a lot," including the launches of RYZEN CPUs, Vega GPUs and the new EPYC server chip. 5. Etsy (ETSY) downgraded to Hold from Buy at Loop Capital with analyst Blake Harper saying with Etsy's new management team undertaking an internal strategic and operational review, an imminent sale of the company is unlikely. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/17/17
GSCO
05/17/17
DOWNGRADE
GSCO
Buy
Pandora downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman analyst Heath Terry removed Pandora from the Conviction Buy List given the slower than expected launch of Premium. Terry said he was wrong in thinking the market would focus on new subscription products and a return to profitability by Q4. Investors are clearly more focused on execution issues of unexpected financing needs and attempts to sell its recently acquired ticketing business, along with increasing competition, the analyst wrote. Terry continues to rate Pandora a Buy with a $16 price target given the significant strategic value of the user base, home screen position, and advertising inventory data, and believes a strategic actions are likely.
BLMN Bloomin' Brands
$20.59

-0.3 (-1.44%)

04/13/17
OTRG
04/13/17
UPGRADE
OTRG
Mixed
Bloomin' Brands upgraded to Mixed from Negative at OTR Global
OTR Global upgraded Bloomin' Brands to Mixed saying checks indicate Q1 same-store-sales are flat to up slightly year-over-year.
05/19/17
WELS
05/19/17
DOWNGRADE
Target $22
WELS
Market Perform
Bloomin' Brands downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jeff Farmer downgraded Bloomin' Brands to Market Perform saying Street estimates could prove aggressive due to labor costs while share repurchases are decelerating. The analyst lowered his price target for the shares to $22 from $24.
02/23/17
02/23/17
DOWNGRADE
Target $19

Neutral
Bloomin' Brands downgraded to Neutral at Credit Suisse
As previously reported, Credit Suisse analyst Jason West downgraded Bloomin' Brands to Neutral from Outperform following weak Q4 results and outlook, and as he sees few fundamental catalysts from here. The analyst also lowered his price target on the shares to $19 from $21.
02/23/17
FBCO
02/23/17
DOWNGRADE
FBCO
Neutral
Bloomin' Brands downgraded to Neutral from Outperform at Credit Suisse
BKE The Buckle
$16.23

-1.1715 (-6.73%)

05/19/17
DBAB
05/19/17
DOWNGRADE
Target $16
DBAB
Sell
The Buckle downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Tiffany Kanaga downgraded The Buckle to Sell citing a lack of near-term support post the Q1 report and continued long-term concerns. The analyst expects negative same-store-sales to drive a 20% decline in earnings in each of the next three years. She keeps a $16 price target for the shares.
04/07/17
DBAB
04/07/17
UPGRADE
Target $16
DBAB
Hold
The Buckle upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Tiffany Kanaga upgraded The Buckle to Hold saying she sees near-term valuation support with the stock down 52% in the past year. The analyst believes the retailer's good momentum can extend at least into April. She upped her price target for the shares to $16 from $15.
05/23/16
KEYB
05/23/16
NO CHANGE
KEYB
Some retailers better positioned than others to adopt to trends, says KeyBanc
After attending the Shoptalk conference, KeyBanc says that some retailers are better positioned than others to adopt to changing trends in the sector. Better positioned retailers include those "with compelling experiences," including Nordstrom (JWN), and those "with strong consumers connections," such as Lululemon (LULU), VF Corp (VFC), Oxford Industries (OXM), and Under Armour (UA), according to the firm. Conversely, retailers with large store footprints, particularly those with a significant presence in malls, "will continue to see pressure," KeyBanc believes. Among the companies in the latter category are L Brands (LB), Zumiez (ZUMZ), The Buckle (BKE), and Francesca's (FRAN), according to the firm.
SHPG Shire
$190.00

7.83 (4.30%)

03/07/17
LEHM
03/07/17
INITIATION
LEHM
Overweight
Shire reinstated with an Overweight at Barclays
After his firm dropped coverage in June 2016, Barclays analyst Emmanuel Papadakis reinstated Shire with an Overweight rating and GBP 65 price target. The rating is unchanged from last year.
03/07/17
LEHM
03/07/17
NO CHANGE
LEHM
European Pharma raised to Positive from Neutral at Barclays
Barclays analyst Emmanuel Papadakis rolled out coverage of the European Pharmaceuticals space and upgraded his sector view to Positive from Neutral. The analyst has "high conviction that the recent transformational era of R&D innovation is set to continue," which he believes will allow the sector to retain pricing power. Papadakis put Overweight ratings on AstraZeneca (AZN), Roche (RHHBY) and Shire (SHPG), with Astra his top pick. The analyst put an Equal Weight rating on GlaxoSmithKline (GSK) and Underweight ratings on Sanofi (SNY), Novartis (NVS) and Novo Nordisk (NVO).
04/10/17
STFL
04/10/17
NO CHANGE
STFL
Shire new HAE drug likely to be momentum driver, says Stifel
Stifel analyst Annabel Samimy says that there is a high probability that Shire's SHP643, a SubQ, once- or twice-monthly prophylactic treatment for hereditary angioedema, will be successful, as the analyst says that the drug would "present a meaningful advance to current prophylactic treatment" of the disease. The analyst thinks that the treatment could expand the market for prophylaxis, as the current standard of care is administered through IV, and she expects it to create momentum for Shire's stock. Samimy notes that Phase 3 data on the drug is expected to be released soon. She keeps a $250 price target and a Buy rating on the shares.
05/19/17
HSBC
05/19/17
DOWNGRADE
HSBC
Reduce
Shire downgraded to Reduce from Hold at HSBC
HSBC analyst Steve McGarry downgraded Shire to Reduce saying that while the hereditary angioedema data are positive, invesotrs should avoid the "hemophilia risk." The analyst believes the Baxalta deal could hurt return on invested capital if competition in hemophilia "gets notably more severe." He lowered his price target for Shire shares to 4,450p from 4,550p.
SYMC Symantec
$29.74

-0.38 (-1.26%)

05/19/17
RBCM
05/19/17
DOWNGRADE
RBCM
Sector Perform
Symantec downgraded on valuation at RBC Capital
As noted earlier, RBC Capital downgraded Symantec to Sector Perform from Outperform. Analyst Matthew Hedberg downgraded the stock based on valuation. Target $32.
05/18/17
05/18/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Symantec (SYMC) downgraded to Neutral from Buy at UBS with analyst Fatima Boolani citing a more balanced risk/reward. 2. Jack in the Box (JACK) downgraded to Sector Weight from Overweight at KeyBanc and to Market Perform from Outperform at Telsey Advisory. 3. Grainger (GWW) downgraded to Sell from Hold at Deutsche Bank with analyst John Inch saying the company is "positioned to quickly lose share" as competitors respond with price cuts of their own. 4. Stratasys (SSYS) downgraded to Hold from Buy at Jefferies with analyst James Kisner citing the recent rally in the shares and uncertainty around the timing of new manufacturing opportunities. The analyst raised his price target for the stock to $30 from $24 following the company's first quarter results. 5. Endologix (ELGX) was downgraded to Equal Weight from Overweight at Stephens, to Neutral from Buy at BTIG, and to Hold from Buy at Stifel. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/18/17
UBSW
05/18/17
DOWNGRADE
Target $33
UBSW
Neutral
Symantec downgraded to Neutral at UBS
As previously reported, UBS analyst Fatima Boolani downgraded Symantec to Neutral from Buy on a more balanced risk/reward. The analyst said the consensus bullish view of earnings and growth expectations is already priced into the stock. Boolani raised her price target to $33 from $31 on Symantec shares.
05/19/17
RBCM
05/19/17
DOWNGRADE
RBCM
Sector Perform
Symantec downgraded to Sector Perform from Outperform at RBC Capital

TODAY'S FREE FLY STORIES

WHR

Whirlpool

$182.50

0.04 (0.02%)

07:20
10/24/17
10/24
07:20
10/24/17
07:20
Technical Analysis
Technical View: Whirlpool down sharply as results, view, miss expectations »

The stock is set to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 14

    Nov

07:20
10/24/17
10/24
07:20
10/24/17
07:20
General news
FX Update: The dollar has traded firmer »

FX Update: The dollar has…

GLW

Corning

$30.01

-0.05 (-0.17%)

07:19
10/24/17
10/24
07:19
10/24/17
07:19
Hot Stocks
Corning sees every business segment to meet or beat plan in Q4 »

"Year-to-date…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

HNI

HNI Corporation

$42.29

-0.57 (-1.33%)

07:19
10/24/17
10/24
07:19
10/24/17
07:19
Downgrade
HNI Corporation rating change  »

HNI Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

PTCT

PTC Therapeutics

$16.99

-0.8 (-4.50%)

07:19
10/24/17
10/24
07:19
10/24/17
07:19
Conference/Events
Breaking Conference/Events news story on PTC Therapeutics »

FDA PDUFA Date for PTC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 02

    Nov

  • 06

    Nov

GLW

Corning

$30.01

-0.05 (-0.17%)

07:18
10/24/17
10/24
07:18
10/24/17
07:18
Earnings
Corning reports Q3 core EPS 43c, consensus 41c »

Reports Q3 GAAP revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

HYGS

Hydrogenics

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Conference/Events
TMX Group to hold a conference »

TSX Industrial &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 16

    Nov

THR

Thermon Group

$21.40

0.4 (1.90%)

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Recommendations
Thermon Group analyst commentary  »

Thermon Group price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGA

Pegasystems

$59.15

-0.3 (-0.50%)

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Recommendations
Pegasystems analyst commentary  »

Pegasystems should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHW

Sherwin-Williams

$386.58

-3.12 (-0.80%)

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Technical Analysis
Technical View: Sherwin-Williams slips lower after results »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

ELVT

Elevate Credit

$7.52

-0.14 (-1.83%)

, FPAY

FlexShopper

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Conference/Events
Stephens to hold meetings at conference »

Stephens Hosted Company…

ELVT

Elevate Credit

$7.52

-0.14 (-1.83%)

FPAY

FlexShopper

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

CTMX

CytomX Therapeutics

$20.04

-0.12 (-0.60%)

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Initiation
CytomX Therapeutics initiated  »

CytomX Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$171.27

-3.71 (-2.12%)

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Periodicals
Facebook faces EU-wide privacy fights after top court setback, Bloomberg says »

Facebook may faces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 01

    Nov

  • 08

    Nov

  • 15

    Nov

HFC

HollyFrontier

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Downgrade
HollyFrontier rating change  »

HollyFrontier downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

PBF

PBF Energy

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Downgrade
PBF Energy rating change  »

PBF Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPX

Louisiana-Pacific

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Initiation
Louisiana-Pacific initiated  »

Louisiana-Pacific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VLO

Valero

07:14
10/24/17
10/24
07:14
10/24/17
07:14
Downgrade
Valero rating change  »

Valero downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

DK

Delek US

07:14
10/24/17
10/24
07:14
10/24/17
07:14
Upgrade
Delek US rating change  »

Delek US upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

ALDW

Alon USA Partners

$11.74

0.05 (0.43%)

07:14
10/24/17
10/24
07:14
10/24/17
07:14
Upgrade
Alon USA Partners rating change  »

Alon USA Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Conference/Events
Drug Information Association to hold a conference »

Biosimilars Conference is…

PEBO

Peoples Bancorp

$33.03

-0.79 (-2.34%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Earnings
Peoples Bancorp reports Q3 EPS 60c, consensus 50c »

Reports Q3 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

WY

Weyerhaeuser

$34.82

-0.46 (-1.30%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Initiation
Weyerhaeuser initiated  »

Weyerhaeuser initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

ALXN

Alexion

$135.21

-3.81 (-2.74%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Recommendations
Alexion analyst commentary  »

Alexion could be up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

  • 06

    Nov

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Hot Stocks
Breaking Hot Stocks news story on Pentair »

Pentair: Separation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:12
10/24/17
10/24
07:12
10/24/17
07:12
Earnings
Pentair sees FY17 adjusted EPS $3.53, consensus $3.51 »

Sees FY17 sales $4.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.